Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma

doi:10.1186/s13014-016-0644-4

CNU IR > College of Smart Living > Dept. of Information Management > Periodical Articles > Item 310902800/30980

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/30980

題名:	Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
作者:	Leung, Henry W. C. Liu, Chung-Feng Chan, Agnes L. F.
貢獻者:	China Med Univ, An Nan Hosp, Dept Radiat Therapy Min Hwei Coll Hlth Care Management, Dept Nursing Chia Nan Univ Pharm & Sci, Dept Informat Management China Med Univ, An Nan Hosp, Dept Pharm
關鍵詞:	Cost-effectiveness analysis ICER Advanced hepatocellular carcinoma Sorafenib
日期:	2016-05
上傳時間:	2018-01-18 11:39:08 (UTC+8)
出版者:	Biomed Central Ltd
摘要:	Objective: Stereotactic body radiotherapy (SBRT) has been shown to improve overall survival in patients with advanced hepatocellular carcinoma. This study aimed to assess the cost-effectiveness of SBRT compared to sorafenib which is the only drug for advanced hepatocellular carcinoma. Methods: A Markov decision-analytic model was performed to compare the cost-effectiveness of SBRT and sorafenib for unresectable advanced hepatocellular carcinoma. Patients transitioned between three health states: stable disease, progression disease and death. We calculated the data on cost from the perspective of our National Health Insurance Bureau. Sensitivity analyses were conducted to determine the impact of several variables. Results: The incremental cost effectiveness ratio (ICER) for sorafenib compared to SBRT was NT$ 3,788,238 per quality-adjusted life year gained (cost/QALY), which was higher than the willingness to pay threshold of Taiwan according to WHO's guideline. One-way sensitivity analysis revealed that the utility of progression disease for the sorafenib treatment, utility of progression free survival for SBRT, utility of progression free survival for sorafenib, utility of PFS to progression disease for SBRT and transition probability of progression disease to dead for SBRT were the most sensitive parameters in all cost scenarios. The Monte-Carlo simulation demonstrated that the probability of cost-effectiveness at a willingness to pay threshold of NT$ 2,213,145 per QALY was 100 % and 0 % chance for SBRT and sorafenib. Conclusion: This study indicated that SBRT for advanced hepatocellular carcinoma is cost-effective at a willingness to pay threshold as defined by WHO guideline in Taiwan.
關聯:	Radiation Oncology, v.11, 69
顯示於類別:	[Dept. of Information Management] Periodical Articles

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
30980.pdf		1066Kb	Adobe PDF	440	檢視/開啟
index.html		0Kb	HTML	1752	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....